OA
SCLN

OFI Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

OFI Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,843
Closed -$28K – 1727
2015
Q2 		$28K Buy
+2,843
New +$25.9K ﹤0.01% 1638

Other funds holding SCLN

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return

OFI Advisors's SCLN Position: Q3 2015 in Review

OFI Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2015, closing a stake of 2,843 shares — an estimated $28K sold.

OFI Advisors first reported a position in SCLN in Q2 2015 and held it in 1 quarter. The position peaked at $28K in Q2 2015. 134 funds tracked by Wall St. Rank hold SCLN as of Q3 2015.

  • OFI Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • OFI Advisors sold 2,843 Sciclone Pharmaceuticals Inc shares in Q3 2015, an estimated $28K.
  • OFI Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 1 quarter.
  • OFI Advisors's Sciclone Pharmaceuticals Inc position peaked at $28K in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2015.

Based on OFI Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.